NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by HC Wainwright

NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by HC Wainwright to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q3 2026 earnings at ($0.59) EPS.

Several other equities research analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Guggenheim lifted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday. Royal Bank Of Canada raised their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Trading Up 2.7%

Shares of NAMS stock opened at $35.58 on Thursday. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $42.00. The stock has a fifty day simple moving average of $33.97 and a two-hundred day simple moving average of $32.54. The stock has a market capitalization of $4.03 billion, a price-to-earnings ratio of -20.57 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. Research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This represents a 7.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $774,425.40. The trade was a 57.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 298,647 shares of company stock valued at $10,236,050. Company insiders own 20.84% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its position in shares of NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares during the period. Capital World Investors boosted its position in shares of NewAmsterdam Pharma by 1.6% during the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after buying an additional 161,289 shares during the period. Jennison Associates LLC grew its stake in shares of NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after buying an additional 697,129 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.